Market news

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. W

Access the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S.

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

Outlook Therapeutics (OTLK) said late Thursday it appointed Kevin Lundquist as chief financial offic

Kevin Lundquist Kevin Lundquist Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LY

Video webcast now available here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference. During the segment, Mr. Jahr highlighted why he believes Outlook Therapeuti

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.

Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upcoming launch plans for LYTENAVA. Over the last 5 years, Outlook Therapeutics has delivered a share price decline of about 98%, which shows how much long term holders have seen their investment erode. The planned U.S. commercial launch of FDA approved LYTENAVA, funded in part by a roughly US$55m...

Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities Potential to exceed $500 million in annual U.S. LYTENAVA sales by 2030 Company to host corporate update conference call today, August 14th, at 8:30 AM ET — registration details below ISELIN, N.J., Aug

Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.

Outlook Therapeutics (OTLK) priced a public offering of about 55.6 million common shares and accompa

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a

Outlook Therapeutics (OTLK) said late Wednesday it has started an underwritten public offering of it

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined p

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. The call will be hosted by members of Out

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

Outlook Therapeutics (OTLK) has received U.S. Food and Drug Administration approval for LYTENAVA, the first ophthalmic bevacizumab formulation cleared for treating neovascular age related macular degeneration. This approval places the company directly in the large U.S. anti VEGF retina market. See our latest analysis for Outlook Therapeutics. Despite FDA approval and a recent broker upgrade, Outlook Therapeutics’ recent share price return has been volatile. The stock is down 15% over the past...

Outlook Therapeutics previously announced that the FDA approved LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration, making it the first and only FDA-approved ophthalmic bevacizumab for this condition in the United States. An interesting aspect of this approval is Outlook’s expectation of 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act, in a US anti-VEGF retina market estimated at about US$8.50 billion...

On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.’s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet AMD. The regulatory milestone distinguishes LYTENAVA as the inaugural and sole FDA-approved ophthalmic...

BTIG upgraded the stock to ‘Buy’ from ‘Neutral’ after Outlook Therapeutics received regulatory approval for its wet AMD therapy.

The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.

Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.

Outlook Therapeutics (NASDAQ:OTLK) shares rose approximately 8. 9% in pre-market trading as investors continued to react positively to the U.

Outlook expects a U.S. launch before year-end and anticipates 12 years of market exclusivity.

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

LYTENAVA is now the first and only FDA-approved version of the drug bevacizumab specifically made for injection into the eye to treat wet age-related macular degeneration.

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA